Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02957890
PHASE4

Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong

Sponsor: The University of Hong Kong

View on ClinicalTrials.gov

Summary

This study evaluates the immunogenicity of adding inactivated influenza vaccine with southern hemisphere (SH) formulation to standard once-annual influenza vaccination with northern hemisphere (NH) formulation in older adults in Hong Kong over 9 years. Half of participants will receive twice-annual influenza vaccination with NH and SH formulation, while the other half will receive once-annual influenza vaccination with NH formulation and a placebo.

Official title: Immunogenicity of Twice-annual Vaccination Against Seasonal Influenza for Two Hemispheres in Older Adults in Hong Kong - a Randomised Controlled Trial

Key Details

Gender

All

Age Range

70 Years - 79 Years

Study Type

INTERVENTIONAL

Enrollment

400

Start Date

2016-11-18

Completion Date

2026-09

Last Updated

2023-12-11

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Inactivated influenza vaccine (NH formulation)

Round 1 (November): 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation

BIOLOGICAL

Inactivated influenza vaccine (SH formulation)

Round 2 (May): 0.5mL Vaxigrip®, Sanofi Pasteur, containing 45μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the southern hemisphere formulation

BIOLOGICAL

Placebo

Round 2 (May): 0.5mL normal saline

Locations (1)

The University of Hong Kong

Hong Kong, China